J&J sues American Red Cross over signature emblem
US health care major Johnson & Johnson has filed a law suit in the Southern District Court of New York against the American Red Cross and four of its licensing partners for "unlawful conduct" related to the for-profit use of the Red Cross emblem. J&J alleges that the Red Cross licensed the emblem design to for-profit companies that sell medical products, such as first-aid kits and hand sanitizers, and infringed the firm's trade mark, which it registered as early as 1906.
J&J says that it has tried for several months to resolve the situation without recourse to the courts, and maintains that the Red Cross only has the right to use the trade mark for non-profit relief services.
Specifically, J&J demands that the Red Cross:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze